Purpose of this Study
People in the study will get a special medicine called CTIM-76 through a tube in their arm once a week. Each round of treatment lasts 4 weeks. They can keep getting the medicine as long as it helps and doesn’t cause too many problems. Doctors will check on them often with visits, blood tests, and scans to see if the medicine is working and if it’s safe. Some people will start with small doses, and the amount may go up as doctors learn more.
Who Can Participate?
Eligibility
To join the study, people must be 18 years or older. They need to have certain cancers—like ovarian, testicular, or uterine cancer—that came back or kept growing after regular treatments. Their cancer must have a special protein called Claudin-6, except for testicular cancer, which doesn’t need that test. They also need to feel well enough to do everyday things and have healthy blood and organs based on lab tests.
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
This study is trying out a new medicine called CTIM-76 to see if it’s safe and if it can help treat certain cancers. These cancers have a special protein called Claudin-6. Doctors want to find the best amount of medicine to use and see if it can make the cancer smaller or slow it down.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
Yes
Study Details
Full Title
A Phase 1, First-in-Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients with Recurring Ovarian Cancer and Other Advanced Solid Tumors
Principal Investigator
Christopher
Hoimes
Protocol Number
PRO00118895
NCT ID
NCT06515613
Phase
I
Enrollment Status
Pending Open to Enrollment